[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338794-105":59,"doc-detail-338794-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","chimeric-antigen-receptor-t-cell-therapy-for-pancreatic-cancer-a-review-of-current-evidence","Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer - A Review of Current Evidence","","Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment approaches for malignant and non-malignant conditions through genetically modified immune effector cells that recognize specific surface antigens and eliminate targets. CAR T cells can mediate cytotoxic effects via multiple pathways, including perforin and granzyme, Fas/FasL, and cytokine secretion. This review consolidates pre-clinical and clinical evidence on tumor-associated antigens, CAR-T toxicities, and therapeutic efficacy in pancreatic cancer, especially for solid tumors resistant to standard oncology.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chimeric-antigen-receptor-t-cell-therapy-for-pancreatic-cancer-a-review-of-current-evidence/338794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chimeric-antigen-receptor-t-cell-therapy-for-pancreatic-cancer-a-review-of-current-evidence/338794.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is CAR T-cell therapy and how does it work?","Question",{"text":113,"@type":114},"CAR T-cell therapy uses genetically modified immune cells expressing synthetic receptors that recognize specific surface antigens on target cells, leading to elimination through cytotoxic mechanisms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is immunotherapy limited in pancreatic cancer?",{"text":118,"@type":114},"Pancreatic cancer creates an immunosuppressive tumor microenvironment, including dense desmoplasia and immunosuppression, which restricts the effectiveness of approaches such as immune checkpoint inhibitors.",{"name":120,"@type":111,"acceptedAnswer":121},"Which aspects does the review cover for CAR-T therapy in pancreatic cancer?",{"text":122,"@type":114},"The review summarizes current pre-clinical and clinical studies focusing on potential tumor-associated antigens, CAR-T toxicities, and therapeutic efficacy in pancreatic cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338794,1790174378,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","cells  \nReview  \nChimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence  \nAgata Czaplicka 1, Mieszko Lachota 2, Leszek Pa˛czek 3, Radosław Zagodon 2 and Beata Kaleta 3, *  \nCitation: Czaplicka, A.; Lachota, M.; Pa˛czek, L.; Zagoz˙ dz˙ on, R.; Kaleta, B. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: AReview of Current Evidence. Cells 2024, 13, 101. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells13010101](10.3390/cells13010101)  \nAcademic Editors: Stephen Todryk and Tilili Barhoumi  \nReceived: 27 November 2023  \nRevised: 19 December 2023  \nAccepted: 2 January 2024  \nPublished: 4 January 2024  \nCorrection Statement: This article has been republished with a minor change. The change does not affect the scientific content of the article and further details are available within the backmatter of the website version of this article.  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Internal Medicine and Gastroenterology, Mazovian “Bródnowski” Hospital, 03-242 Warsaw, Poland; [agata.sieczkowska23@gmail.com](agata.sieczkowska23@gmail.com)  \n2 Laboratory of Cellular and Genetic Therapies, Medical University of Warsaw, 02-091 Warsaw, Poland; [mieszko.lachota@wum.edu.pl](mieszko.lachota@wum.edu.pl) (M.L.); [radoslaw.zagozdzon@wum.edu.pl](radoslaw.zagozdzon@wum.edu.pl) (R.Z.)  \n3 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland; [leszek.paczek@wum.edu.pl](leszek.paczek@wum.edu.pl)  \n* [Correspondence: beata.kaleta@wum.edu.pl](Correspondence: beata.kaleta@wum.edu.pl); Tel.: +48-600-301-690  \nAbstract: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of malignant and non-malignant disorders. CARs are synthetic transmembrane receptors expressed on genetically modified immune effector cells, including T cells, natural killer (NK) cells, or macrophages, which are able to recognize specific surface antigens on target cells and eliminate them. CAR-modified immune cells mediate cytotoxic antitumor effects via numerous mechanisms, including the perforin and granzyme pathway, Fas and Fas Ligand (FasL) pathway, and cytokine secretion. High hopes are associated with the prospective use of the CAR-T strategy against solid cancers, especially the ones resistant to standard oncological therapies, such as pancreatic cancer (PC) . Herein, we summarize the current pre-clinical and clinical studies evaluating potential tumor-associated antigens (TAA), CAR-T cell toxicities, and their efficacy in PC.  \nKeywords: adoptive cell therapy; CAR T cells; chimeric antigen receptor; immunotherapy; pancreatic cancer  \n1. Introduction  \nPancreatic cancer (PC) is the 12th most common cancer and the 7th leading cause of cancer-related death worldwide [1] . This type of malignancy has a poor prognosis due to delayed diagnosis and limited therapeutic options. The 5-year relative survival rate for PC is 12%[2] . Therefore, the early detection and identification of molecular therapeutic targets improve the prospects for long-term survival. According to data published in 2023 by the National Cancer Institute, 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDACs), which are predicted to be the second leading cause of cancer-related death by 2030 [3,4] .  \nPC is associated with numerous risk factors, including age, sex, tobacco smoking, overweight and obesity, hyperglycemia, insulin resistance, type 2 diabetes, pancreatitis, as well as genetic factors (mutations in BRCA1, BRCA2, PALB2, ATM, STK11/LKB1, P16INK4A/CDKN2A, KRAS5, and TP53 genes) [5] . Gene expression analyses allowed the identifica","cbCaii5MegNQLHJ1","https://ap.wps.com/l/cbCaii5MegNQLHJ1","pdf",972048,16,"English","# Abstract\n# 1. Introduction\n# 2. Immunotherapy Challenges in Pancreatic Cancer","[{\"question\":\"What is CAR T-cell therapy and how does it work?\",\"answer\":\"CAR T-cell therapy uses genetically modified immune cells expressing synthetic receptors that recognize specific surface antigens on target cells, leading to elimination through cytotoxic mechanisms.\"},{\"question\":\"Why is immunotherapy limited in pancreatic cancer?\",\"answer\":\"Pancreatic cancer creates an immunosuppressive tumor microenvironment, including dense desmoplasia and immunosuppression, which restricts the effectiveness of approaches such as immune checkpoint inhibitors.\"},{\"question\":\"Which aspects does the review cover for CAR-T therapy in pancreatic cancer?\",\"answer\":\"The review summarizes current pre-clinical and clinical studies focusing on potential tumor-associated antigens, CAR-T toxicities, and therapeutic efficacy in pancreatic cancer.\"}]","Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer - A Review of Current Evidence | PDF",1790025728,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0cc62709ad954b836d707aaf5ce9241.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b3d7c992e5e40b2e48801361371d6d1.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6293dd0e651f766a93b3b11b6621dcd0.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ab1ba940fb981e8cc6eb1faaa962058.webp",980,1385]